Mobile
Recherche simple
Recherche avancée
Recherche multicritère
Qui sommes-nous ?
Connexion
Inscription
French
English
Kusajili – Centralise les essais cliniques mondiaux
Résultat
de votre recherche par promoteur : Merck Sharp & Dohme Corp
Femme et Homme Max 99 ans
Merck Sharp & Dohme Corp
MAJ Il y a 4 ans
A Phase II Randomized, Placebo-Controlled Clinical Trial to Study the Safety and Immunogenicity of V212 in Adult Patients with Autoimmune Disease Ensayo clínico en fase II, aleatorizado y controlado con placebo para estudiar la seguridad y la inmunogenicidad de V212 en pacientes adultos con enfermedades autoinmunitarias
1) To determine whether V212 is immunogenic when administered to adult patients with autoimmune disease. 2) To assess the safety and tolerability of V212 in adult patients with autoimmune disease. ...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
unknown
Plus d'informations
Femme et Homme Max 99 ans
Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc
MAJ Il y a 4 ans
A clinical trial to test if the combination of ertugliflozin with Sitagliptin is safe and effective when compared to ertugliflozin alone and Sitagliptin alone in patients with Type 2 Diabetes whose sugar levels are not well controlled by their current treatment with Metaformin
In subjects with T2DM and inadequate glycemic control on metformin ≥1500 mg/day, after 26 weeks: 1. To assess the A1C-lowering efficacy of the addition of ertugliflozin 15 mg q.d. plus sitagliptin 10...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
Merck Sharp & Dohme Corp
MAJ Il y a 4 ans
A Phase II Clinical Trial to Study the Efficacy and Safety of the combination regimen of MK-5172 + MK-8742 + Ribavirin (R) in Subjects with Chronic Hepatitis C Virus Infection Ensayo Clínico en fase II para estudiar la eficacia y seguridad del régimen combinado de MK-5172 + MK-8742 + Ribavirina (RBV) en pacientes con infección crónica por el virus de la hepatitis C
In subjects with chronic HCV GT 1 infection who have failed prior DAA + PR treatment, with pre-treatment HCV RNA of at least 10,000 IU/mL: -To evaluate the efficacy of MK-5172 in combination with MK-8...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
Merck Sharp & Dohme Corp., a subsidary of Merck & Co., Inc
MAJ Il y a 4 ans
MK-3475 (pembrolizumab) in subjects with Classical Hodgkin Lymphoma
To determine the safety, tolerability and Overall Response Rate (ORR) of pembrolizumab in each of the three cohorts listed below. Cohort 1: Subjects with relapsed/refractory classical Hodgkin Lymp...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
unknown
Plus d'informations
Femme et Homme Max 99 ans
Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc
MAJ Il y a 4 ans
A Phase II Study of Pembrolizumab in Subjects with Triple-Negative Breast Cancer
(1) Objective (Cohorts A+C): To evaluate the Overall Response Rate (ORR) to pembrolizumab as 2L+ monotherapy in subjects with PD-L1 strong (+) centrally confirmed mTNBC, based on RECIST 1.1 as assesse...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
unknown
Plus d'informations
Femme et Homme Max 99 ans
Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc
MAJ Il y a 4 ans
Study to test the safety, tolerability, and effectiveness of sitagliptin when compared to placebo in reducing the amount of insulin (with or without metformin) needed per day, to control blood sugar, over a 24-week period
After 24 weeks, to assess the effect of sitagliptin compared with placebo on the change in insulin dose in IU per day in patients with type 2 diabetes mellitus (T2DM) with inadequate glycemic control ...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
unknown
Plus d'informations
Femme et Homme Max 99 ans
Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc
MAJ Il y a 4 ans
Phase III Randomized Controlled Trial of Pembrolizumab with or without Chemo vs Chemo in Advanced Urothelial Carcinoma
To compare Progression Free Survival (PFS) using RECIST 1.1 as assessed by (Blinded Independent Central Review) BICR and Overall Survival (OS) in PD-L1 positive subjects and all subjects with advanced...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
unknown
Plus d'informations
Femme et Homme Max 99 ans
Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc
MAJ Il y a 4 ans
A study to evaluate the safety and efficacy of the addition of a new drug (MK-3102) compared with the addition of a licensed drug (Glimepiride) in patients with Type 2 Diabetes
After 54 weeks, to assess the A1C-lowering efficacy of MK-3102 compared to glimepiride. To assess the safety and tolerability of MK-3102.
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
Merck Sharp & Dohme Corp
MAJ Il y a 4 ans
A Clinical Trial to Test Different Doses of MK-5172 administered with Other Hepatitis C Virus Treatments
(1) To evaluate the efficacy of each treatment arm of MK-5172 in combination with peg-IFN and RBV as assessed by the proportion of subjects achieving SVR12 (Sustained Virologic Response 12 weeks after...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
Merck Sharp & Dohme Corp
MAJ Il y a 4 ans
Phase III study of efficacy, safety and tolerability of two human monoclonal antibodies to Clostridium Difficile toxin A and B, in patients receiving antibiotic therapy. Studio di fase III per valutare l'efficacia, la sicurezza e la tollerabilita' di due anticorpi monoclonali umani verso le tossine A e B del batterio Clostridium Difficile, in pazienti in trattamento con terapia antibiotica
assess whether MK-3415A given with the standard of care antibacterial therapy (SOC) relative to MK-3415, MK-6072, and placebo given with SOC reduces CDI recurrence over a period of 12 weeks and to ...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Précédent
1
2
3
4
5
6
7
8
9
10
Suivant